Research News and Research

RSS

The Chinese acute coronary syndrome drug market to grow from $326M in 2010 to $448M in 2015

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the acute coronary syndrome (ACS) drug market in China will grow from $326 million in 2010 to $448 million in 2015.

21 Nov 2011

State roundup: Provider groups merging - or not

A selection of health policy stories from California, Illinois, Georgia, Connecticut, Minnesota, Michigan and Massachusetts.

21 Nov 2011

Medicare physician pay cut again in play

Because the deficit panel's prospects are increasingly dim, efforts to intervene to prevent a 27 percent reduction in Medicare physician payment are becoming increasingly dire.

21 Nov 2011

Kiewit-Turner intensifies construction activities at medical center project for Colorado's veterans

Kiewit-Turner, a joint venture, has begun mobilizing additional workers and equipment as construction activities intensify on the Department of Veterans Affairs' medical center project.

21 Nov 2011

ADA Seal of Acceptance helps consumers make informed decisions about dental products

For more than 125 years, the American Dental Association (ADA) has been evaluating dental products for safety and effectiveness. The ADA Seal of Acceptance, which is a registered certification mark, is awarded after a product is tested and meets ADA guidelines and standards. The Pennsylvania Dental Association encourages you to shop wisely and purchase dental care products with the ADA Seal.

21 Nov 2011

2011 National Report Card on Lung Cancer notes significant change in grade for early detection

Today, Lung Cancer Alliance (LCA), the leading national support and advocacy voice for those at risk for or living with lung cancer, issued its annual 2011 National Report Card on Lung Cancer, an overall assessment of the nation's response to the continuing high mortality of lung cancer, the leading cause of cancer death.

21 Nov 2011

Akebia commences dosing in AKB-9778 Phase 1 study for diabetic macular edema and retinopathy

Akebia Therapeutics, Inc., a small molecule discovery and development company focused on anemia and vascular disorders, today announced that it has dosed the first subjects in a first-in-man Phase 1 study of AKB-9778, a first-in-class human protein tyrosine phosphatase beta (HPTPβ) inhibitor in development for diabetic macular edema (DME) and diabetic retinopathy (DR).

21 Nov 2011

Health experts identify gap in medical trainee programs

Globalization has led to significant changes in the health care of children worldwide, yet medical education in the developed world has remained domestically focused. Canadian pediatricians are caring for growing numbers of new immigrants, refugees and international adoptees, so their formal training should reflect these changes.

21 Nov 2011

Medizone, SMTC enter partnership to manufacture AsepticSure disinfection system

Medizone International, a leading-edge research and development company that specializes in decontamination and sterilization systems and SMTC Corporation, a global electronics manufacturing services provider, today jointly announce a new partnership agreement to manufacture Medizone's AsepticSure disinfection system.

21 Nov 2011

Australia's TGA grants market authorisation for Pierre Fabre Médicament's milnacipran to treat fibromyalgia

The Therapeutic Goods Administration (TGA), Australia's regulatory body for therapeutic products, granted Pierre Fabre Médicament's milnacipran market authorisation for the treatment of fibromyalgia.

21 Nov 2011

PLoS ONE publishes study on darinaparsin, a multivalent chemotherapeutic

ZIOPHARM Oncology, Inc. announced today the publication of a darinaparsin (Zinapar or ZIO-101) study in the PLoS ONE, an international, peer-reviewed, open-access, online publication of the Public Library of Science.

21 Nov 2011

WaferGen third quarter revenue decreases to $89,000

WaferGen Biosystems, Inc., an emerging genomic analysis company, today reported financial results for the three and nine months ended September 30, 2011 and announced a revised plan to commercialize and increase adoption of its SmartChip System.

21 Nov 2011

UTHealth and Memorial Hermann HVI first in Houston to implant FDA approved artificial heart valve

Cardiologists and cardiovascular surgeons at The University of Texas Health Science Center at Houston and Memorial Hermann Heart & Vascular Institute are the first in Houston to implant the artificial heart valve recently approved by the Food and Drug Administration, as well as a newer, smaller version that is part of a clinical trial.

21 Nov 2011

EU's FP7 programme provides €6M grant for Thyroid Hormone Replacement for Subclinical Hypo-Thyroidism Trial

Dr Patricia Kearney, Department of Epidemiology & Public Health, UCC is one of a group of researchers from European Universities who will participate in a new research project investigating current treatment practices for people who suffer from a mildly underactive thyroid gland.

21 Nov 2011

Gilead enters agreement for Pharmasset acquisition

Gilead Sciences, Inc. and Pharmasset, Inc. announced today that the companies have signed a definitive agreement under which Gilead will acquire Pharmasset for $137 per share in cash.

21 Nov 2011

Cancer Research UK initiates recruitment for Stratified Medicine Programme

Cancer Research UK has started recruiting patients for a pioneering initiative to demonstrate how genetic tests could be used within the NHS to help match cancer patients to the most appropriate treatment, while building a database of information for research into new targeted therapies.

21 Nov 2011

ShangPharma third quarter net revenues increase 24.7% to $28.8 million

ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced its unaudited financial results for the quarter ended September 30, 2011.

21 Nov 2011

ICON selected as CRO for Tasly's Dantonic pill global Phase III studies for chronic stable angina pectoris

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been selected by Tasly Pharmaceuticals for the company's global Phase III T89 trial. T89, also known as Dantonic pill, aims to become the first traditional Chinese medicine to receive FDA approval in the United States.

21 Nov 2011

New blood pressure remote monitoring program for Stamford employees, families

Stamford Hospital has launched a new blood pressure remote monitoring program for its employees and their families in order to detect risk factors for heart disease while helping to improve their overall health.

21 Nov 2011

South Asian cardiac patients three times as likely to require repeat treatment following PCI

South Asian patients with coronary artery disease were almost three times as likely to be readmitted to hospital for further interventional treatment to arterial plaque than their White European counterparts, according to research in the December issue of IJCP, the International Journal of Clinical Practice.

21 Nov 2011

Research News and Research

The Chinese acute coronary syndrome drug market to grow from $326M in 2010 to $448M in 2015

State roundup: Provider groups merging - or not

Medicare physician pay cut again in play

Kiewit-Turner intensifies construction activities at medical center project for Colorado's veterans

ADA Seal of Acceptance helps consumers make informed decisions about dental products

2011 National Report Card on Lung Cancer notes significant change in grade for early detection

Akebia commences dosing in AKB-9778 Phase 1 study for diabetic macular edema and retinopathy

Health experts identify gap in medical trainee programs

Medizone, SMTC enter partnership to manufacture AsepticSure disinfection system

Australia's TGA grants market authorisation for Pierre Fabre Médicament's milnacipran to treat fibromyalgia

PLoS ONE publishes study on darinaparsin, a multivalent chemotherapeutic

WaferGen third quarter revenue decreases to $89,000

UTHealth and Memorial Hermann HVI first in Houston to implant FDA approved artificial heart valve

EU's FP7 programme provides €6M grant for Thyroid Hormone Replacement for Subclinical Hypo-Thyroidism Trial

Gilead enters agreement for Pharmasset acquisition

Cancer Research UK initiates recruitment for Stratified Medicine Programme

ShangPharma third quarter net revenues increase 24.7% to $28.8 million

ICON selected as CRO for Tasly's Dantonic pill global Phase III studies for chronic stable angina pectoris

New blood pressure remote monitoring program for Stamford employees, families

South Asian cardiac patients three times as likely to require repeat treatment following PCI

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News